Company
Day One Biopharmaceuticals, Inc.
Headquarters: South San Francisco, CA, United States
Employees: 55
CEO: Dr. Jeremy Bender M.B.A., Ph.D.
Market Cap
$689.3 Million
USD as of July 1, 2025
Day One Biopharmaceuticals, Inc. Categories
United States Healthcare BiotechnologyUnited States Healthcare United States Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $309.91 B |
| Vertex Pharmaceuticals Incorporated | $117.36 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $59.14 B |
| Marinomed Biotech AG | $58.56 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
Detailed Description
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Financials
| Last Financial Reports Date | March 31, 2025 |
| Revenue TTM | $161.9 M |
| EBITDA | $-189,212,000 |
| Gross Profit TTM | $153.8 M |
| Profit Margin | -42.66% |
| Operating Margin | -133.50% |
| Quarterly Revenue Growth | 5.32% |
Stocks & Indices
Day One Biopharmaceuticals, Inc. has the following listings and related stock indices.
Stock: NASDAQ: DAWN wb_incandescent